Who has invested in Nucleai?

Section32, Sanofi, Debiopharm, Vertex Ventures, Grove Ventures, Merck's VC arm are named among the investors backing Nucleai.

Nucleai Funding: $50M Raised, Series B

Nucleai funding overview

Nucleai is based in Israel. Nucleai has raised $50M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B. Investors on record include Section32, Sanofi, Debiopharm, Vertex Ventures, Grove Ventures, Merck's VC arm. 6 distinct backers are named across the disclosed rounds.

Nucleai at a glance

Total raised: $50M
Latest round: Series B
Headquarters: Israel
Notable investors: Section32, Sanofi, Debiopharm, Vertex Ventures, Grove Ventures, Merck's VC arm

Frequently asked about Nucleai funding

How much has Nucleai raised?: Nucleai has raised $50M in total disclosed funding across the rounds on record.
Who has invested in Nucleai?: Section32, Sanofi, Debiopharm, Vertex Ventures, Grove Ventures, Merck's VC arm are named among the investors backing Nucleai.
What was the latest Nucleai funding round?: The most recent disclosed round is a Series B.
Where is Nucleai based?: Nucleai is based in Israel.

Totals shown for Nucleai aggregate every disclosed round on file. To see how that compares, browse the companies in Israel and the investors behind them below.

Nucleai Funding: $50M Raised, Series B

Nucleai funding overview

Nucleai at a glance

Frequently asked about Nucleai funding

Companies related to Nucleai (20)

Browse related funding lists (5)